H.R. 1947: Treatment and Relief through Emerging and Accessible Therapy for PTSD Act

This bill, known as the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act (or TREAT PTSD Act), aims to expand access to a specific treatment known as stellate ganglion block (SGB) for individuals suffering from post-traumatic stress disorder (PTSD). Below are the key provisions of the bill:

Provision of Stellate Ganglion Block for Veterans

The bill mandates the following:

1. Eligibility for Veterans: The Secretary of Veterans Affairs is required to provide the stellate ganglion block to veterans who meet these criteria:
   • They must be enrolled in the patient enrollment system of the Department of Veterans Affairs.
   • They must have a diagnosis of PTSD.
   • They must choose to receive the SGB treatment after being informed of its risks and benefits by a qualified health care provider.
2. Provision of Care: The treatment may be provided at a Department of Veterans Affairs medical facility or through a specified external health care provider.

Provision of Stellate Ganglion Block for Members of the Armed Forces

Similar provisions will be made for active-duty members of the Armed Forces, including those in reserve components, with the following specifics:

1. Eligibility for Service Members: The Secretary of Defense is required to provide SGB to any service member who:
   • Is enrolled in the TRICARE program.
   • Has a diagnosis of PTSD.
   • Chooses to receive the SGB treatment after being informed of the risks and benefits.
2. Provision of Care: As with veterans, care may be provided through a Department facility or a qualified provider in the TRICARE system.

Guideline Updates

The bill requires that within 180 days of its enactment, the Secretary of Veterans Affairs and the Secretary of Defense must update current clinical practice guidelines associated with PTSD management. This update should:

1. Reflect the availability of stellate ganglion block as a treatment option.
2. Include information regarding clinical indicators and contraindicators related to the use of SGB.

Notification Requirements

Once the guidelines are updated, the Secretaries must notify the relevant congressional committees about the changes made.

Effective Date

The provisions concerning the stellate ganglion block treatment will take effect 180 days after the bill is enacted into law.

Relevant Companies

None found